EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Ubrogepant: Mechanism of action, clinical and translational science

Ramesh Boinpally iD, Mohamad Shebley iD, Joel Trugman iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13675 ↗

At a glance

Journal article in Clinical and Translational Science, 2024. Written by Ramesh Boinpally and 2 co-authors. Institution: Clinical Pharmacology, AbbVie, North Chicago, Illinois, USA. Major MEDLINE topics: Translational Science, Biomedical, Migraine Disorders, Pyridines, Pyrroles. Cited 8 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

In recent years, the treatment of migraine has experienced a breakthrough in the development of drugs that target the calcitonin gene‐related peptide (CGRP) signaling pathway. Monoclonal antibodies against the receptor or ligand have been developed for the preventive treatment of migraine; whereas, orally administered small molecule CGRP receptor antagonists, called gepants, have been developed for both acute and/or preventive treatment. Both modalities have demonstrated safe and effective treatment of migraine, reducing the number of migraine days for patients as well as reducing symptoms and improving patient function and overall quality of life. Here, we provide an abridged review of ubrogepant, an oral CGRP receptor antagonist, approved for the acute treatment of migraine. We briefly summarize the role of CGRP in migraine pathophysiology, describing the mechanism of action of ubrogepant in the context of this pathway, the clinical pharmacology properties and the clinical development and outcomes, including safety, efficacy, pharmacokinetics, and pharmacodynamics, that supported ubrogepant's approval.

Subjects

MeSH terms (MEDLINE)

Translational Science, BiomedicalMigraine DisordersPyridinesPyrrolesHumansCalcitonin Gene-Related PeptideQuality of Life

Substances

ubrogepantCalcitonin Gene-Related PeptidePyridinesPyrroles

Authors and institutions

  • Clinical Pharmacology, AbbVie, North Chicago, Illinois, USA.
  • Clinical Development, AbbVie, North Chicago, Illinois, USA.

ORCID profiles: Ramesh Boinpally, Mohamad Shebley, Joel Trugman

Cite

APA

Boinpally, R., Shebley, M., & Trugman, J. (2024). Ubrogepant: Mechanism of action, clinical and translational science. Clinical and Translational Science. https://doi.org/10.1111/cts.13675

Vancouver

Boinpally R, Shebley M, Trugman J. Ubrogepant: Mechanism of action, clinical and translational science. Clinical and Translational Science. 2024. doi:10.1111/cts.13675

BibTeX
@article{Boinpally2024,
  author = {Boinpally, Ramesh and Shebley, Mohamad and Trugman, Joel},
  title = {Ubrogepant: Mechanism of action, clinical and translational science},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13675}
}
Start for free →